<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36435844</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Seroepidemiology of enterovirus A71 infection in prospective cohort studies of children in southern China, 2013-2018.</ArticleTitle><Pagination><StartPage>7280</StartPage><MedlinePgn>7280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-34992-1</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71)-related hand, foot, and mouth disease (HFMD) imposes a substantial clinical burden in the Asia Pacific region. To inform policy on the introduction of the EV-A71 vaccine into the National Immunization Programme, we investigated the seroepidemiological characteristics of EV-A71 in two prospective cohorts of children in southern China conducted between 2013 and 2018. Our results show that maternal antibody titres declined rapidly in neonates, with over half becoming susceptible to EV-A71 at 1 month of age. Between 6 months and 2 years of age, over 80% of study participants were susceptible, while one third remained susceptible at 5 years old. The highest incidence of EV-A71 infections was observed in children aged 5-6 months. Our findings support EV-A71 vaccination before 6 months for birth cohorts in southern China, potentially with a one-time catch-up vaccination for children 6 months-5 years old. More regionally representative longitudinal seroepidemiological studies are needed to further validate these findings.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5028-2227</Identifier><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liao</LastName><ForeName>Qiaohong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Luo</LastName><ForeName>Kaiwei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention (Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences), Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Fengfeng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Yonghong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1242-1764</Identifier><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zou</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention (Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences), Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shuanbao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Xianglin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Bingbing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Anhua County Center for Disease Control and Prevention, Yiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmeyer</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medusa Therapeutics Limited, Hong Kong Special Administrative Region, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hongan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Anhua County Center for Disease Control and Prevention, Yiyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paireau</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5143-6256</Identifier><AffiliationInfo><Affiliation>Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Department, Santé publique France, Saint-Maurice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lidong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention (Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences), Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolay</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Shixiong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention (Workstation for Emerging Infectious Disease Control and Prevention, Chinese Academy of Medical Sciences), Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Weijia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Key Laboratory of Surveillance and Early-warning on Infectious Disease, Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Tai'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Doorn</LastName><ForeName>H Rogier</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horby</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><Identifier Source="ORCID">0000-0002-9822-1586</Identifier><AffiliationInfo><Affiliation>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmonds</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leung</LastName><ForeName>Gabriel M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-2503-6283</Identifier><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowling</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauchemez</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9186-4549</Identifier><AffiliationInfo><Affiliation>Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, UMR2000, CNRS, 75015, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hongjie</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6335-5648</Identifier><AffiliationInfo><Affiliation>School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China. yhj@fudan.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ISSF204826/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>H.Y. has received investigator-initiated research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company and SINOVAC Biotech Ltd. None of the research funding is related to this study. All other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>26</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36435844</ArticleId><ArticleId IdType="pmc">PMC9701185</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34992-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-34992-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097–1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect. Dis. 2014;14:308–318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill.22, pii=16-00824 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, et al. Population based hospitalization burden of laboratory-confirmed hand, foot and mouth disease caused by multiple enterovirus serotypes in southern China. PLoS ONE. 2018;13:e0203792. doi: 10.1371/journal.pone.0203792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203792</ArticleId><ArticleId IdType="pmc">PMC6292616</ArticleId><ArticleId IdType="pubmed">30543631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109:e88. doi: 10.1542/peds.109.6.e88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.109.6.e88</ArticleId><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, et al. Incidence rates of enterovirus 71 infections in young children during a nationwide epidemic in Taiwan, 2008-09. PLoS Negl. Trop. Dis. 2012;6:e1476. doi: 10.1371/journal.pntd.0001476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001476</ArticleId><ArticleId IdType="pmc">PMC3279337</ArticleId><ArticleId IdType="pubmed">22348156</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014;370:829–837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention. Guidelines for use of inactivated enterovirus type 71 vaccine. Chin. J. Vaccines Immun. 2016;22:458–464.</Citation></Reference><Reference><Citation>Zheng J, et al. Immunization coverage of the national immunization program vaccines at the township level, based on a survey conducted by provincial CDCs in China, 2013. Chin. J. Vaccines Immun. 2014;20:492–498.</Citation></Reference><Reference><Citation>Long Y, et al. Study on the uptake of inactivated enterovirus A71 vaccine in Guangdong province in 2017. South China J. Prev. Med. 2018;44:349–351.</Citation></Reference><Reference><Citation>Wu L, Liu J, Shao H, Sun X. Surveillance for coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with EV71 vaccine among children in Shanghai. Chin. J. Vaccines Immun. 2020;26:62–66.</Citation></Reference><Reference><Citation>Zeng J, et al. Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell) Zhonghua Yu Fang. Yi Xue Za Zhi. 2019;53:252–257.</Citation><ArticleIdList><ArticleId IdType="pubmed">30841662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang LW, et al. The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect. Dis. 2011;11:270. doi: 10.1186/1471-2334-11-270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-11-270</ArticleId><ArticleId IdType="pmc">PMC3198955</ArticleId><ArticleId IdType="pubmed">21988931</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang LW, et al. Seroepidemiology of coxsackievirus A6, coxsackievirus A16, and enterovirus 71 infections among children and adolescents in Singapore, 2008-2010. PLoS ONE. 2015;10:e0127999. doi: 10.1371/journal.pone.0127999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127999</ArticleId><ArticleId IdType="pmc">PMC4444285</ArticleId><ArticleId IdType="pubmed">26011735</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwood PF, et al. Seroepidemiology of human enterovirus 71 infection among children, Cambodia. Emerg. Infect. Dis. 2016;22:92–95. doi: 10.3201/eid2201.151323.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2201.151323</ArticleId><ArticleId IdType="pmc">PMC4696711</ArticleId><ArticleId IdType="pubmed">26690000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China. Virol. J. 2012;9:248. doi: 10.1186/1743-422X-9-248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-248</ArticleId><ArticleId IdType="pmc">PMC3545860</ArticleId><ArticleId IdType="pubmed">23102275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, et al. Retrospective seroepidemiology indicated that human enterovirus 71 and coxsackievirus A16 circulated wildly in central and southern China before large-scale outbreaks from 2008. Virol. J. 2010;7:300. doi: 10.1186/1743-422X-7-300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-300</ArticleId><ArticleId IdType="pmc">PMC2989968</ArticleId><ArticleId IdType="pubmed">21050463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, et al. Seroepidemiology of coxsackievirus A6, coxsackievirus A16, and enterovirus 71 infections in infants and children: a prospective cohort study in Jiangsu, China. J. Infect. 2016;73:509–512. doi: 10.1016/j.jinf.2016.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2016.08.008</ArticleId><ArticleId IdType="pubmed">27546063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran CB, et al. The seroprevalence and seroincidence of enterovirus71 infection in infants and children in Ho Chi Minh City, Viet Nam. PLoS ONE. 2011;6:e21116. doi: 10.1371/journal.pone.0021116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021116</ArticleId><ArticleId IdType="pmc">PMC3134465</ArticleId><ArticleId IdType="pubmed">21765891</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, et al. Seroprevalence of enterovirus 71 antibody among children in China: a systematic review and meta-analysis. Pediatr. Infect. Dis. J. 2015;34:1399–1406. doi: 10.1097/INF.0000000000000900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000900</ArticleId><ArticleId IdType="pmc">PMC4718881</ArticleId><ArticleId IdType="pubmed">26368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS ONE. 2012;7:e37206. doi: 10.1371/journal.pone.0037206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037206</ArticleId><ArticleId IdType="pmc">PMC3360679</ArticleId><ArticleId IdType="pubmed">22662137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei X, et al. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study. Lancet Infect. Dis. 2021;21:418–426. doi: 10.1016/S1473-3099(20)30480-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30480-1</ArticleId><ArticleId IdType="pubmed">33031750</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, et al. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin. Med. J. 2010;123:1679–1684.</Citation><ArticleIdList><ArticleId IdType="pubmed">20819628</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, et al. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2022;399:1708–1717. doi: 10.1016/S0140-6736(22)00313-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00313-0</ArticleId><ArticleId IdType="pubmed">35427481</ArticleId></ArticleIdList></Reference><Reference><Citation>Honkanen PO, Keistinen T, Kivela SL. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. Vaccine. 1997;15:317–320. doi: 10.1016/S0264-410X(96)00171-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(96)00171-5</ArticleId><ArticleId IdType="pubmed">9139492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubba L, et al. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect. Dis. 2020;20:350–361. doi: 10.1016/S1473-3099(19)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30566-3</ArticleId><ArticleId IdType="pubmed">31870905</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K, et al. Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study. Lancet Infect. Dis. 2019;20:230–239. doi: 10.1016/S1473-3099(19)30632-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30632-2</ArticleId><ArticleId IdType="pmc">PMC11284833</ArticleId><ArticleId IdType="pubmed">31859216</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J. Biomed. Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778–790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, et al. Pathogen spectrum of hand, foot, and mouth disease based on laboratory surveillance — China, 2018. China CDC Wkly. 2020;2:167–172. doi: 10.46234/ccdcw2020.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2020.044</ArticleId><ArticleId IdType="pmc">PMC8393163</ArticleId><ArticleId IdType="pubmed">34594617</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, et al. Spectrum of enterovirus serotypes causing uncomplicated hand, foot, and mouth disease and enteroviral diagnostic yield of different clinical samples. Clin. Infect. Dis. 2018;67:1729–1735. doi: 10.1093/cid/ciy341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy341</ArticleId><ArticleId IdType="pubmed">29688329</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, et al. Hand, foot, and mouth disease in china: modeling epidemic dynamics of enterovirus serotypes and implications for vaccination. PLoS Med. 2016;13:e1001958. doi: 10.1371/journal.pmed.1001958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001958</ArticleId><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev. Vaccines. 2018;17:819–831. doi: 10.1080/14760584.2018.1510326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, et al. Expression of caspid protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection. J. Med. Virol. 2000;61:228–234. doi: 10.1002/(SICI)1096-9071(200006)61:2&lt;228::AID-JMV9&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(200006)61:2&lt;228::AID-JMV9&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">10797379</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming. China Emerg. Microbes Infect. 2021;10:619–628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H, et al. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36:3445–3452. doi: 10.1016/j.vaccine.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.005</ArticleId><ArticleId IdType="pubmed">29739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Liu CC, Chow YH, Chou AH, Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797–803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, et al. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals. Hum. Vaccin Immunother. 2015;11:2723–2733. doi: 10.1080/21645515.2015.1011975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1011975</ArticleId><ArticleId IdType="pmc">PMC4685687</ArticleId><ArticleId IdType="pubmed">25715318</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Q, et al. Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017–2019. EBioMedicine. 2021;68:103398. doi: 10.1016/j.ebiom.2021.103398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103398</ArticleId><ArticleId IdType="pmc">PMC8170117</ArticleId><ArticleId IdType="pubmed">34049245</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29:9668–9674. doi: 10.1016/j.vaccine.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo K, et al. Hand, foot, and mouth disease in Hunan province, China, 2009–2014: epidemiology and death risk factors. PLoS ONE. 2016;11:e0167269. doi: 10.1371/journal.pone.0167269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0167269</ArticleId><ArticleId IdType="pmc">PMC5127556</ArticleId><ArticleId IdType="pubmed">27898715</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio Laboratory Manual, 4th ed. (World Health Organization, 2004).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>